SNG.L
Synairgen plc [SNG.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SNG.L Stock Summary
In the News
SNG.L Financial details
Company Rating
-
Market Cap
12.69M
Income
-38.14M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
34
Optionable
No
Shortable
Yes
Earnings
25 Apr 2024
P/E
-0.68
Forward P/E
-
PEG
0.32
P/S
-
P/B
0.6
P/C
-
P/FCF
-0.84
Quick Ratio
6.05
Current Ratio
7.19
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.19
EPS next Y
-
EPS next Q
-
EPS this Y
-63.5%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
20.35%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-9.23%
-
-
-
-
SMA20
-46.41%
SMA50
-52.45%
SMA100
-70.69%
Inst Own
-
Inst Trans
-
ROA
-75%
ROE
-62%
ROC
-1%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.0-17.5
52W High
-94.41%
52W Low
-76.25%
RSI
36.48
Rel Volume
5.93
Avg Volume
411.66K
Volume
2.44M
Perf Week
5.56%
Perf Month
-54.33%
Perf Quarter
-
Perf Half Y
-71.21%
-
-
-
-
Beta
-2.22613
-
-
Volatility
0.04%, 0.5%
Prev Close
0%
Price
0.95
Change
17.87%
Company Profile
- Volume Average 411.66K
- Market Capitalization 12.69M
- Employee 34
- CEO Mr. Richard Marsden
- Headquarters Southampton,GB
- IPO Date 2004-10-26
-
Website
https://www.synairgen.com 
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
